ARTICLE FROM KACTUS

Article: From Oncology to Autoimmunity: The “Old” Target CD20 Still Holds Great Promise

Natasha Slepak from KACTUS has recently published a fascinating read on the evolution of a classic research target: “From Oncology to Autoimmunity: The ‘Old’ Target CD20 Still Holds Great Promise.” While traditionally studied in hematological malignancies, CD20 targeting is now opening an exciting new chapter in preclinical models of severe immune disorders.

Expressed exclusively on the surface of B-cells, CD20 has been the foundational target for developing early monoclonal antibodies. Because of this success, it remains a premier target for researchers developing next-generation modalities in the lab, including bispecific T-cell engagers and CAR-T cells.

How Does CD20 Targeting Function in Autoimmune Models?

While aberrant B-cells cause certain blood cancers, they are also the primary drivers of refractory autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, and Multiple Sclerosis. In these disease models, hyperactive B-cells produce autoantibodies that attack healthy tissue.

Advanced CD20 targeting interventions address this by:

• Targeted Depletion: Achieving a deep, systemic depletion of pathogenic B-cells in the in vivo model.

• Immune System Reset: Wiping out the dysfunctional B-cell compartment allows the immune system to “reboot”.

• Healthy Repopulation: Post-intervention, healthy, non-autoreactive B-cells are allowed to repopulate the system.

Preclinical data suggests that redirecting these advanced modalities could pave the way for functional cures for diseases historically considered lifelong burdens, providing a massive shift in how researchers approach autoimmunity in the lab.